Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q2 2018 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2018-08-14

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q2 2018 (← Previous) (Next →)

Filing Date: Aug 14, 2018

Total Value: $293M (100.0% shares, 0.0% debt)

Holdings (17)

INSM Insmed Incorporated 14.5%

Value $42.58M Shares 1,800,587 Est. Cost $27.89 Unrealized -7.7%

— Biohaven Pharmaceutical Holding Company Ltd. 11.5%

Value $33.64M Shares 851,200 Est. Cost $26.07 Unrealized —

— Immunomedics, Inc. 9.9%

Value $29.15M Shares 1,231,543 Est. Cost $17.13 Unrealized —

— Myokardia, Inc. 9.6%

Value $28.09M Shares 565,755 Est. Cost $45.40 Unrealized —

— CymaBay Therapeutics, Inc. 9.3%

Value $27.15M Shares 2,023,369 Est. Cost $9.20 Unrealized —

— OptiNose, Inc. 8.9%

Value $25.98M Shares 928,545 Est. Cost $23.29 Unrealized —

RYTM Rhythm Pharmaceuticals, Inc. 7.7%

Value $22.57M Shares 721,903 Est. Cost $27.09 Unrealized +0.9%

ABUS Arbutus Biopharma Corporation 6.6%

Value $19.36M Shares 2,651,825 Est. Cost $5.62 Unrealized +6.0%

ASND Ascendis Pharma A/S 6.1%

Value $17.99M Shares 270,424 Est. Cost $40.06 Unrealized —

— Alder BioPharmaceuticals, Inc. 6.1%

Value $17.87M Shares 1,130,919 Est. Cost $13.27 Unrealized —

ACRS Aclaris Therapeutics, Inc. 3.6%

Value $10.57M Shares 529,551 Est. Cost $22.18 Unrealized -16.7%

— Alder BioPharmaceuticals, Inc. 1.9%

Value $5.53M Shares 350,000 Est. Cost — Unrealized —

— Eidos Therapeutics, Inc. 1.7%

Value $4.985M Shares 245,082 Est. Cost $20.34 Unrealized —

RCUS Arcus Biosciences, Inc. 1.2%

Value $3.611M Shares 295,000 Est. Cost $16.66 Unrealized -5.8%

— Tricida, Inc. 0.8%

Value $2.243M Shares 75,000 Est. Cost $29.91 Unrealized —

— Kiniksa Pharmaceuticals, Ltd. 0.6%

Value $1.639M Shares 94,477 Est. Cost $17.35 Unrealized —

QURE uniQure N.V. 0.1%

Value $403K Shares 10,650 Est. Cost $15.23 Unrealized +110.3%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
INSM	Insmed Incorporated	1,800,587	$42.58M	14.5%	$27.89	-7.7%	COM	457669307
—	Biohaven Pharmaceutical Holding Company Ltd.	851,200	$33.64M	11.5%	$26.07	—	COM	G11196105
—	Immunomedics, Inc.	1,231,543	$29.15M	9.9%	$17.13	—	COM	452907108
—	Myokardia, Inc.	565,755	$28.09M	9.6%	$45.40	—	COM	62857M105
—	CymaBay Therapeutics, Inc.	2,023,369	$27.15M	9.3%	$9.20	—	COM	23257D103
—	OptiNose, Inc.	928,545	$25.98M	8.9%	$23.29	—	COM	68404V100
RYTM	Rhythm Pharmaceuticals, Inc.	721,903	$22.57M	7.7%	$27.09	+0.9%	COM	76243J105
ABUS	Arbutus Biopharma Corporation	2,651,825	$19.36M	6.6%	$5.62	+6.0%	COM	03879J100
ASND	Ascendis Pharma A/S	270,424	$17.99M	6.1%	$40.06	—	SPONSORED ADR	04351P101
—	Alder BioPharmaceuticals, Inc.	1,130,919	$17.87M	6.1%	$13.27	—	COM	014339105
ACRS	Aclaris Therapeutics, Inc.	529,551	$10.57M	3.6%	$22.18	-16.7%	COM	00461U105
—	Alder BioPharmaceuticals, Inc.	350,000	$5.53M	1.9%	—	—	Put	014339955
—	Eidos Therapeutics, Inc.	245,082	$4.985M	1.7%	$20.34	—	COM	28249H104
RCUS	Arcus Biosciences, Inc.	295,000	$3.611M	1.2%	$16.66	-5.8%	COM	03969F109
—	Tricida, Inc.	75,000	$2.243M	0.8%	$29.91	—	COM	89610F101
—	Kiniksa Pharmaceuticals, Ltd.	94,477	$1.639M	0.6%	$17.35	—	Class A Common	G5269C101
QURE	uniQure N.V.	10,650	$403K	0.1%	$15.23	+110.3%	SHS	N90064101